Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Jeet will be a trusted partner in cardiovascular care
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Subscribe To Our Newsletter & Stay Updated
